Administration ofSCPE could significantly inhibit LXR-α, SREBP-1c and FAS gene expression, and offer effective treatment for high fat dietinduced NAFLD. This evidence concerns the gene NR1H3 and metabolic dysfunction-associated steatotic liver disease.